NASDAQ · LTRN
Lantern Pharma Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for LTRN: Nov 11, 2026
Lantern Pharma Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.39.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · RTTNews · Fintel · Quiver Quantitative- The Motley Fool · Aug 21, 8:28 AM EDTLantern Pharma (LTRN) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- The Motley Fool · May 21, 10:39 AM EDTLantern Pharma (LTRN) Q1 2025 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Mar 31, 10:04 AM EDTLantern's Q4 Net Loss Narrows; Type C Meeting With FDA For LP-300 Ahead In Mid – May 2026; Stock Up(RTTNews) – Lantern Pharma Inc. (LTRN), a clinical-stage company, announced fourth-quarter and full-year 2025 financial results reflecting a narrower net loss. In addition, the firm provided an update on its portfolio of AI-driven drug candidates.
- RTTNews · Mar 30, 4:08 AM EDTLantern Pharma Shares Rise; What's The Buzz?(RTTNews) – Lantern Pharma Inc. (LTRN), a clinical-stage pharmaceutical company, shares surged over 30% to $1.45 in the pre-market after the firm and its subsidiary Starlight Therapeutics announced that the U.S. Food and Drug Administration (FDA) had cleared the Investigational N
- Fintel · Mar 27, 12:50 PM EDTLantern Pharma (LTRN) Price Target Increased by 25.00% to 25.50The average one-year price target for Lantern Pharma (NasdaqCM:LTRN) has been revised to $25.50 / share. This is an increase of 25.00% from the prior estimate of $20.40 dated February 21, 2026. The price target is an average of many targets provided by analyst
- RTTNews · Mar 27, 11:34 AM EDTLantern Pharma Stock Falls 10% After FDA Clears Investigational New Drug Application For STAR-001(RTTNews) – Stock of Lantern Pharma Inc. (LTRN) is moving down about 10 percent on Friday morning trading after the company, along with its subsidiary Starlight Therapeutics, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application
- RTTNews · Jan 20, 10:14 AM ESTLantern Pharma Receives FDA Orphan Drug Designation For LP-284(RTTNews) – Lantern Pharma Inc. (LTRN) on Tuesday announced, that the U.S. Food and Drug Administration has given Orphan Drug Designation to LP-284 for treatment of soft tissue sarcomas.
- RTTNews · Dec 3, 9:08 AM ESTLantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors(RTTNews) – Lantern Pharma Inc. (LTRN), a clinical-stage biotechnology company, on Wednesday shared additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184.
- RTTNews · Sep 16, 9:03 AM EDTLantern Pharma Says Phase 1a Study Of LP-184 Met All Primary Endpoints In Advanced Solid Tumors(RTTNews) – Lantern Pharma Inc. (LTRN) announced Tuesday that its Phase 1a study evaluating the drug candidate LP-184 in patients with advanced solid tumors, including Glioblastoma Multiforme (GBM), an aggressive form of brain cancer, met all primary endpoints.
- The Motley Fool · Aug 13, 6:18 PM EDTLantern Pharma Narrows Loss in Q2GAAP EPS loss narrowed to ($0.40) per share in Q2 2025, and improving from ($0.46) per share (GAAP) in Q2 2024.
- Quiver Quantitative · Jul 8, 11:31 AM EDT$LTRN stock is up 13% today. Here's what we see in our data.$LTRN stock has now risen 13% today, according to our price data from Polygon. There has been approximately $11,661,056 of trading volume.
- Quiver Quantitative · Jun 13, 6:15 AM EDTInsider Sale: 10% owner at $LTRN Sells 21,557 SharesAaron G.L. Fletcher, a 10% owner of $LTRN, sold 21,557 shares of the company on 06-12-2025 for an estimated $72,862. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.3% of their shares of this class of stock. Following this trade, they no
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Lantern Pharma Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.